TearLab Corporation (OTCMKTS: TEAR) and Cooper Companies, Inc. (The) (NYSE:COO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.
Insider and Institutional Ownership
19.5% of TearLab Corporation shares are held by institutional investors. Comparatively, 96.7% of Cooper Companies, Inc. (The) shares are held by institutional investors. 12.0% of TearLab Corporation shares are held by company insiders. Comparatively, 1.6% of Cooper Companies, Inc. (The) shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares TearLab Corporation and Cooper Companies, Inc. (The)’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|TearLab Corporation||$28.01 million||0.15||-$19.92 million||($2.98)||-0.24|
|Cooper Companies, Inc. (The)||$1.97 billion||5.84||$273.91 million||$6.97||33.67|
Cooper Companies, Inc. (The) has higher revenue and earnings than TearLab Corporation. TearLab Corporation is trading at a lower price-to-earnings ratio than Cooper Companies, Inc. (The), indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
TearLab Corporation has a beta of 2.92, suggesting that its stock price is 192% more volatile than the S&P 500. Comparatively, Cooper Companies, Inc. (The) has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
Cooper Companies, Inc. (The) pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. TearLab Corporation does not pay a dividend. Cooper Companies, Inc. (The) pays out 0.9% of its earnings in the form of a dividend.
This table compares TearLab Corporation and Cooper Companies, Inc. (The)’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cooper Companies, Inc. (The)||16.45%||16.00%||9.90%|
This is a summary of current ratings and price targets for TearLab Corporation and Cooper Companies, Inc. (The), as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cooper Companies, Inc. (The)||0||5||7||0||2.58|
TearLab Corporation currently has a consensus price target of $5.75, suggesting a potential upside of 709.86%. Cooper Companies, Inc. (The) has a consensus price target of $260.63, suggesting a potential upside of 11.06%. Given TearLab Corporation’s stronger consensus rating and higher probable upside, analysts plainly believe TearLab Corporation is more favorable than Cooper Companies, Inc. (The).
Cooper Companies, Inc. (The) beats TearLab Corporation on 10 of the 15 factors compared between the two stocks.
TearLab Corporation Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor’s office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.
Cooper Companies, Inc. (The) Company Profile
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses. CooperVision services three primary regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. CooperVision offers spherical, aspherical, toric, multifocal and toric multifocal lens products in various modalities. CooperVision’s products are primarily manufactured at its facilities located in the United Kingdom, Puerto Rico, Hungary, Costa Rica and New York. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services focusing on women’s health, fertility and diagnostics.
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.